Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer

NCT00455572 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00455572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
May 11, 2007
Completion date
August 8, 2013
Enrollment
71 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell